GOSS News and Press, Gossamer Bio Inc. From 02/13/21

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast...

Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers

Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials CINCINNATI, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.(Aerpio) (Nasdaq:...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast...

Today, we take an in-depth look at a developmental company with several shots on goal that is well funded. An advancing pipeline and strong analyst support are two other positive factors for a positive risk/reward profile on this concern. A full investment analysis is laid out in ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that the Company’s Board of Directors has ap...

Start Time: 16:30 End Time: 17:30 Gossamer Bio, Inc. (GOSS) Q3 2020 Earnings Conference Call November 10, 2020, 16:30 PM ET Company Participants Sheila Gujrathi - Co-Founder and CEO Bryan Giraudo - CFO Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - SVP, Head of Clinical Developm...

Gossamer Bio (GOSS): Q3 GAAP EPS of -$0.80 beats by $0.04.Cash, equivalents and marketable securities totaled $555M.Shares -0.65%.Press Release For further details see: Gossamer Bio EPS beats by $0.04